2A Pharma ApS products

2A Pharma’s AAVLP-HER2/Neu peptide vaccine candidate has in laboratory tests been shown to induce antibodies specific to human HER2. In mouse models, regression of breast cancer tumors was observed after vaccination. In a proof-of-principle study carried out at the Medical University of Vienna, Austria, supported by Medigene AG, it was concluded that this vaccine strategy could help to establish active immunotherapy for breast-cancer patients. The Medical University of Vienna, Viral particles support prophylactic vaccination against breast cancer.

The global market for prophylactic HPV vaccines is likely to grow rapidly as more and more countries expand national vaccination programs to include HPV vaccinations not only for girls but also for boys. In addition, it is now estimated that 60-70% of oropharyngeal cancers are caused by HPV virus infections, opening up a discussion on HPV vaccinations for adults too.

2A Pharma’s B-cell epitope vaccine candidate, AAVLP-IgE, has in laboratory tests with non-human primates been shown to be effective at inducing anti-IgE autoantibodies. This gives the potential for a vaccine with similar benefits to approved anti-human immunoglobulin E (IgE) antibody treatments of, for example, asthma, nut allergy etc. Currently, the potential of a bivalent AAVLP-IgE vaccine is being investigated.

2A Pharma’s anti-autoimmune vaccine candidate has potential in a number of indications. The vaccine is currently being tested in a vitiligo model in collaboration with different partners.

2A Pharma’s anti-amyloid-beta vaccine candidate, AAVLP-Amyloid-β, has in laboratory tests with transgenic mice over-expressing amyloid-beta mutant protein been shown to eliminate amyloid-beta soluble protein, a clear plaque from the cortex and significantly reduce plaque from the hippocampus. It is our hope that the drug candidate can be developed into a treatment for early-stage Alzheimer’s disease.